What is IRWD's P/E ratio?

IRONWOOD PHARMACEUTICALS INC (IRWD) currently trades at a P/E ratio of 6.01.

IRONWOOD PHARMACEUTICALS INC reports a Return on Equity (ROE) of -47.05%.

What is IRWD's dividend yield?

IRONWOOD PHARMACEUTICALS INC offers a dividend yield of 0.00%.

What is IRWD's Quality Score?

Our AI rates IRWD's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy IRWD?

Our AI Timing Score for IRWD is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does IRWD belong to?

IRONWOOD PHARMACEUTICALS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

IRWD (NASDAQ) Stock Analysis | IRONWOOD PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

IRWD AI Analysis Summary

Our AI summary for IRWD: IRONWOOD PHARMACEUTICALS INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 6.01, ROE of -47.05%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

IRWD

IRONWOOD PHARMACEUTICALS INC

USD 4.23

0.50 (13.40%) Day Change

Watchlist Portfolio Compare Chart

6.01

P/E

-2.71

D/E

-47.1%

ROE

23.5%

ROA

0.00%

Div Yield

0.01

PEG

IRONWOOD PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 4.23 Price 0.50 (13.40%) Day Change	NEWS SCORE: 99

IRWD, the overall quality is ok ( Quality = 69) and the timing to buy is ...(Sign In to See)...

Loading chart...

69 QUALITY

Signal: NEUTRAL

Signal Description: Company financial health is OK

Reason: ROE is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are ok , financial health is not good , and ability to make profit is good , ...

Quality Factors

63%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	430
Magic Formula Rank by ROE	430
Magic Formula Rank by ROIC	109
Price	4.23
PBV / Sector	-2.83 / 3.22
Earning Per Share	0.70

PE / Sector	6.01 / 29.79 GREAT
PEG or PE/Growth / Sector	0.01 / 0.13 GREAT
Average 1M Daily Value	9.01 M
Average 1W Daily Value	7.79 M

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

72%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	28.26 / 15.21 GREAT
NPM Average (%) / Sector	-29.42 / -10.83
NPM Change Average (%) / Sector	663.98 / 117.42 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	23.51 / 8.15 GOOD
ROA Average (%) / Sector	-33.41 / 2.87
ROA Change Average (%) / Sector	265.98 / 112.70 GREAT
ROE (%) / Sector	-47.05 / -1.02
ROE Average (%) / Sector	51.95 / 8.35 GREAT
ROE Change Average (%) / Sector	1,083.08 / 385.91
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.51
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.64

Registration Details

Analyze Date	2026-08-01 08:00:02
Symbol	IRWD
Name	IRONWOOD PHARMACEUTICALS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	164.61 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	614.01 / 10,754.62

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 100 Summer Street, Boston, MA, United States, 02110

Phone: 617 621 7722

Website: https://ironwoodpharma.com

Employees: 100

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.